Pharmaceutical giant Johnson & Johnson (JNJ.US) announced on Wednesday that its proposed drug posdinemab for the treatment of Alzheimer's disease has received Fast Track designation from the USA Food and Drug Administration (FDA).
Johnson & Johnson is conducting a phase 2b study on early Alzheimer's disease patients, focusing on internally discovered tau-directed monoclonal antibodies. The company indicated that posdinemab shows potential against disease-related phosphorylated tau protein in cerebrospinal fluid of Alzheimer's patients and has prevented the development and diffusion of tau protein aggregation in nonclinical models of memory-deprived diseases.
The FDA's Fast Track program is designed to facilitate the development and expedite the review of treatments for serious or life-threatening diseases with unmet medical needs.
